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Abstract: Head and neck squamous cell carcinoma (HNSCC) is a highly heterogeneous disease that 13 
is the result of tobacco and/or alcohol abuse or infection with high-risk Human papillomaviruses. 14 
Despite the fact that the HPV positive HNSCC cancers form a distinct clinical entity with better 15 
treatment outcome, all HNSCC are currently treated uniformly with the same treatment modality. 16 
At present, biologic basis of these different outcomes and their therapeutic influence are areas of 17 
intense investigation. In this review, we will summarize the molecular basis for this different 18 
outcome, novel treatment opportunities and possible biomarkers for HPV positive HNSCC. In 19 
particular, the focus will be on several molecular targeted strategies that can improve the 20 
chemoradiation response by influencing DNA repair mechanisms. 21 
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1 Epidemiology and etiology of HNSCC 24 
Head and neck cancers comprise a group of cancers that are anatomically located in the oral cavity, 25 
the oropharynx, the nasal cavity, paranasal sinuses, the nasopharynx, the hypopharynx and the 26 
larynx. Most of these (90%) cancers have squamous cell carcinoma histology and are called head and 27 
neck squamous cell carcinoma (HNSCC) [1,2].  28 
HNSCC is classified as the 7th most common cancer worldwide with around 600.000 new diagnosis 29 
each year [3]. In United States 50.000 cases are diagnosed each year and nearly 10.000 deaths are 30 
attributable to this disease [4].  31 
HNSCC develops mostly via one of the two primary carcinogenic routes, namely the chemical 32 
carcinogenesis through exposure to tobacco and alcohol abuse, which are known to be synergistic, 33 
and high-risk human papillomavirus (HPV) induced carcinogenesis [1,2,5-7]. Besides the exogenous 34 
risk factors certain inherited disorders such as Fanconi anemia show more susceptibility to HNSCC 35 
[2,8]. 36 
Interestingly, epidemiological studies demonstrated a decrease or stabilization of laryngeal, 37 
hypopharyngeal and oral cavity cancers. This decrease is ascribed to the gradual decrease of the use 38 
of primary exogenous risk factors (smoking and alcohol). In contrast, there is a clear increase in the 39 
incidence rates of oropharyngeal cancers mostly located at base of the tongue (BOT) and tonsillar 40 
region, which is ascribed to the increased incidence of HPV infections [9-11].  41 
 42 
 43 
 44 
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HPV related cancers (HPV+) are mostly located in the oropharynx (predominantly at the tonsils and 45 
tongue base), while only a small fraction of other HNSCC sub-sites have been associated with 46 
high-risk HPV infections [12,13]. Of note, there are discussions about the HPV infections associated 47 
with other HNSCC sub-sites with some seen as a non-specificity of the used HPV detection method 48 
[12,14,15]. A recent analysis performed by Chung et al. shows that HPV infections in other less 49 
common sub-sites are also clinically relevant [16]. A short overview with clinical and biological 50 
differences can be seen in table 1.  51 
 52 
Table 1: Overview of clinical and biological differences between HPV positive and HPV 53 
negative head and neck cancer patients. 54 
 55 
  56 
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The most common high-risk HPV types are HPV16, HPV18, HPV31, HPV33 and HPV35. These 57 
types are estimated to cause about 5% of the cancer burden worldwide, which includes 99% of 58 
cervical cancers, 25- 60% of head and neck cancers, 70% of vaginal cancers, 88% of anal cancers, 43% 59 
vulvar and 50% of penile cancers [17-19]. A significant subset of the 600.000 annual cases of HNSCC 60 
includes approximately 85.000 HPV associated (oropharyngeal) tumors, which means that the head 61 
and neck region is the second most common HPV+ tumor site. In 90% of the HPV associated tumors 62 
HPV16 detection can be seen [17,19]. A noteworthy fact is that at current pace, oropharyngeal cancer 63 
incidence is expected to surpass cervical cancer incidence by 2020 in the United States [10,18,19]. 64 
 65 
The Centers for Disease Control and Prevention classifies high-risk HPV as the most common 66 
sexually transmitted infection in the United States and both oral and genital HPV transmission are 67 
associated with sexual activity. Interestingly, additional risk factors for HPV infections are tobacco, 68 
marijuana and alcohol use [12,20,21].  69 
Apart from their different etiology and epidemiology HPV+ HNSCC tumors show different patient 70 
and clinical characteristics, namely the patients tend to be younger at the time of diagnosis, less 71 
common tobacco and alcohol abusers and have a better socioeconomic status. Furthermore, HPV+ 72 
HNSCC are characterized by poorly differentiated or basaloid histology compared to the HPV- 73 
HNSCC with generally a keratinized histology. Moreover, the HPV+ tumors tend to have large 74 
nodal involvement and small tumor stage. As a consequence the majority of HPV+ HNSCC patients 75 
are diagnosed at clinically advanced stages. However, they also tend to less likely develop 76 
secondary malignancies [9,12,22].  77 
 78 
Interestingly, HPV+ HNSCC patients exhibit an improved outcome to the current treatment options 79 
compared to the HPV- HNSCC [23-26]. The biological basis for this improvement remains unclear. 80 
Several hypotheses have been proposed and will be discussed in the following paragraphs.  81 
2. Molecular pathogenesis of HPV positive HNSCC 82 
Human papillomaviruses are DNA viruses, which can cause a range of epithelial lesions, either 83 
benign or malignant. There are more than 150 different types identified based on DNA sequence 84 
analysis and the viruses are evolutionary divided into distinct groups or genera [27,28]. The alpha 85 
and beta genera include 90% of the current characterized HPV. Beta papillomaviruses are typically 86 
associated with cutaneous infections, but can give rise to non-melanoma related skin cancers in 87 
immune-compromised patients. The alpha genus consists of the largest group of papillomaviruses 88 
and contains the mucosal and cutaneous viruses. The remaining HPVs come from three other genera 89 
namely gamma, Mu and Nu and are generally responsible for cutaneous papillomas and rarely 90 
progress to cancer [27,28]. The viruses are also divided according to their risk of cancer formation, 91 
namely in high-risk and low-risk classes, with high-risk classes having a high association with 92 
cancer formation [27].  93 
 94 
HPV are non-enveloped double-stranded circular DNA viruses with a genome of approximately 95 
8000 kilo base pair. HPV uses the cell cycle progression to replicate itself by infecting the basal cells 96 
of stratified epithelium, which is exposed to the virus by micro-abrasions. The infection results in 97 
subsequent release of HPV DNA in the proliferating basal cells. The viral genome replicates during 98 
the S-phase of the host’s cell cycle and the genome of the virus is equally distributed in the daughter 99 
cells during the host’s replication process, which results in maintenance of low viral copy numbers 100 
in the nucleus of basal dividing cells. Subsequently, the infected cells move further to the upper 101 
epithelial cell layers where also the viral capsid proteins are produced. The amplified viral genome 102 
is packaged into virions and is eventually released during the final stage of the productive life cycle. 103 
It is important to note that virions are not released until the host cell reaches the surface of 104 
epithelium, so HPVs do not have a lytic nature (Figure 1). This life cycle is tightly regulated by 105 
stepwise expression of viral genes, which are coded from the virus genome [27,28]. Of note, the time 106 
of infection and the appearance of productive papillomas can differ depending on the type and titer 107 
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of the virus, with possible latency occurring when inoculating titers are low. On top, experiments 108 
show that the viral transcription can be detected as early as 12h post-infection with mRNA levels 109 
increasing over the course of several days [28].  110 
 111 
Figure 1: A short overview of HPV infection in cells. 112 
 113 
The viral genome can structurally be divided in 3 regions according to their location and function, 114 
namely the early coding region (E), late coding region (L) and non-coding control region. The late 115 
genes are mostly involved in coding of structural proteins, whereas the early genes have important 116 
roles in viral replication and cellular transformation. Briefly, the L1 and L2 genes encode for viral 117 
capsid proteins. The E1 and E2 genes encode for proteins necessary for viral replication. Moreover, 118 
E2 act as a transcription factor and can regulate the viral early promoter and control the expression 119 
of the viral oncogenes E6 and E7. The control is dependent on the expression levels of E2, at lower 120 
expression levels of E2; E2 can act as a transcriptional activator, whereas at high levels it can repress 121 
the expression of the oncogenes E6 and E7. The E4 protein plays a role in maturation and release of 122 
viral proteins. The E5, E6 and E7 genes are necessary for the increase in proliferation in the supra 123 
basal epithelial cells and allow amplification of the virus by disrupting the host’s cell cycle 124 
regulation [28]. Because of the contribution of these genes in cancer formation, they are also named 125 
HPV oncogenes. 126 
Normal HPV infections are not associated with malignant transformation and it is important to 127 
mention that the majority of HPV infections are spontaneously cleared and most patients show an 128 
effective immune response against subsequent HPV infections [12,20,29]. However, recent data 129 
show that high-risk HPV infections are cleared from oral cavity more slowly in comparison with 130 
low-risk HPV infections [29], suggesting the relation with the risk of cancer formation. Cancerous 131 
lesions are recognized by an increased risk of viral DNA integration into the host genome. This will 132 
result in destruction of E2 gene and higher expression of the oncogenes E6 and E7 in basal layer 133 
leading to a disruptive viral infection and incomplete viral life cycle and causes abrogation of cell 134 
cycle checkpoints [28].  135 
E7 binds to cullin 2 ubiquitin ligase complex and results in the disruption and ubiquitination of pRB 136 
and other members of pRB pocket family. The major role of the tumor suppressor protein pRB is the 137 
regulation of G1/S transition of the cell cycle. To understand the function of pRB, it is important to 138 
know how the cell cycle is regulated. Cell cycle progression is tightly controlled by several 139 
checkpoints regulated by complexes of cyclins and cyclin-dependent kinases (CDKs), and inhibitors 140 
of these complexes, namely the CDK inhibitors. To allow cells to progress from G1 to the S phase, 141 
cells have to pass the G1 restriction point, which is controlled by pRB and the pocket proteins p107 142 
(RBL1) and p130 (RBL2). In normal circumstances RB protein is bound to the transcription factor E2F 143 
in its active hypophosphorylated state. This binding results in the inactivation of the E2F 144 
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transcription factors [27,28]. Degradation of pRB protein by E7 will result in activation of E2F and 145 
subsequent translocation to the nucleus, which will stimulate the transcription of S phase genes. The 146 
uncontrolled transcription of S phase genes also leads to the expression of p16INK4a (encoded by 147 
CDKN2A), a CDK inhibitor, as a negative feedback loop, which is also used as surrogate marker for 148 
HPV infections [27,28].  149 
The function of E6 complements the function of E7. E6 binds to E3 ubiquitin ligases and results in 150 
degradation of TP53, which leads to cell cycle deregulation, due to loss of p21 function (CDK 151 
inhibitor) and loss of TP53 mediated apoptosis [27,28].  152 
Although, the HPV oncogenes stimulate cancer formation by promoting limitless replication 153 
potential and genomic instability, cancer formation is stimulated by secondary genetic events.  154 
Before the knowledge of HPV infections and widespread use of (next generation) sequencing, 155 
HNSCC progression was also seen as an accumulation of stepwise (epi)-genetic alterations such as 156 
loss of chromosome 9p21 (CDKN2A loss), acquisition of TP53 mutations, 11q13 amplification 157 
(CCDN1), EGFR overexpression and PTEN inactivation [30]. 158 
Later on, HPV detection in the DNA of HNSCC patients resulted in a novel classification of head 159 
and neck cancers. It was clear that HNSCC are not only heterogeneous in means of their pathology 160 
and anatomical localization but also showed heterogeneity in regards to their biology. In 2012 three 161 
genetic subclasses were suggested by Leemans CR et al. being HNSCC cancer containing the 162 
transcriptionally active HPV that were classified as HPV+ tumors, HPV- tumors accompanied by 163 
high number of genetic changes (high chromosome instability (high CIN)), and HPV- tumors 164 
characterized by low CIN [2].  165 
 166 
Recent progress in molecular technologies (the next generation sequencing and the omics era) gives 167 
definitely an in-depth picture of the molecular aberration in HNSCC. However, further classification 168 
of the heterogeneous group of HNSCC according to their predictive values (therapies) or even 169 
prognostic values is still in its infancy [31,32].  170 
Nonetheless, it was shown that HPV+ tumors have less chromosomal copy number alterations 171 
compared to the HPV- HNSCC. The former is characterized by enrichment of 3q24-27 chromosomal 172 
amplifications, this region is coding for oncogene PIK3CA. The latter is characterized by gain of 173 
11q13, a region encoding for cyclin D1 protein (encoded by CCDN1) [19]. Moreover, high 174 
throughput epigenetic screening experiments suggest differences in epigenetic profiles between 175 
HPV+ and HPV- HNSCC, with former characterized by hyper-methylated regions. However, 176 
further research is necessary to elucidate and validate these differences.  177 
Also on expression level, several studies are performed and Chung et al. classified the HNSCC in 4 178 
groups according to their expression profile: the classical, basal, mesenchymal and atypical group. 179 
The HPV+ group was classified in atypical group and was characterized by up-regulation of cell 180 
cycle and DNA replication genes [2,33]. Of note this classification system was also used by The 181 
Cancer Genome Atlas (TCGA) database [34].  182 
Initial mutational studies revealed that HNSCC have a relatively significant mutational overload 183 
with ranking 9th highest among tumors from 27 anatomical sites. These studies showed a 2 to 5 fold 184 
increase in mutation rates between HPV- and HPV+ HNSCC. However, the latter could not be 185 
verified by the recently published TCGA database, where the mutation rates between the two 186 
groups did not differ. It was noted that mutational profiles of HPV- HNSCC resembled the 187 
smoking-associated lung and esophageal SCC and was characterized with frequent transversions at 188 
CpG regions. The HPV+ HNSCCs meanwhile closely resembles the mutational profile of cervical 189 
cancers and showed higher mutation frequencies in PI3K pathway components and DNA repair 190 
genes [19,31,34]. 191 
3. Treatment response 192 
HNSCC treatment is based on combination of three major treatment arms, namely surgery, 193 
chemotherapy and radiotherapy (RT) [2,35]. For metastasized disease generally systemic treatment 194 
like chemotherapy is preferred. However, in locally advanced disease surgery and RT play an 195 
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important role, this with or without chemotherapy. It is important to note that the goal of RT is to 196 
eradicate tumor cells by delivering the radiation dose to the tumor, and avoiding dose delivery to 197 
surrounding healthy tissues (toxicity). The most important side effects, which are also limiting the 198 
dose of RT delivery and hence outcome, are therefore dysphagia and xerostomia [35,36]. 199 
For early stage localized disease, RT and surgery seems to give similar results on locoregional 200 
control (LRC) and choice is made according to the organ preservation issue [2,37,38]. For locally 201 
advanced disease including HPV+ HNSCC, the addition of concurrent chemotherapy 202 
(platinum-based) to RT showed a 5-year survival benefit of 6.5% and is often considered as standard 203 
care [39].  204 
Interestingly, several retrospective and prospective trials have shown that HPV+ HNSCC patients 205 
have better overall survival (OS), disease free survival (DFS) and locoregional control (LRC) 206 
compared to the HPV- patients and this is independent of the treatment modality. In general the 207 
5-year OS for HPV- HNSCC is around 50% while for HPV+ HNSCC patients values around 80% can 208 
be reached [12,23,25,26,40-44]. It should be highlighted that in these studies the HPV status is 209 
defined post-hoc. Of note, no data are available about the prognostic value of HPV on solely 210 
chemotherapy for primary HNSCC, since this is not the standard treatment modality. However, 211 
HPV status did show a correlation with outcome in metastatic and recurrent HNSCC patients 212 
treated with chemotherapy [45-48].  213 
One of the landmark studies conducted by Ang et al. demonstrated a better 3-year OS (83.4% vs 214 
57.1%) and a 58% reduction of risk of death (HR=0.4; 95% CI 0.27-0.66) in HPV+ HNSCC patients 215 
treated with (chemo)radiotherapy. What makes this study interesting is that the risk of death 216 
increased with each additional pack year of tobacco smoking. The authors suggested a novel 217 
classification system of HNSCC patients on basis of four factors: HPV status, pack-years of tobacco 218 
smoking, tumor stage and nodal stage [40]. The influence of smoking on the outcome of HPV+ 219 
HNSCC patient was recently verified by a pooled analysis of two randomized trials demonstrating 220 
that risk of death increases by 1% for each pack year of tobacco smoking or 2% for each year of 221 
smoking history of the patients [41]. One of interesting observations about the performed studies 222 
involving RT is that HPV positivity results primarily in an improved LRC, but no statistically 223 
significant difference can be seen in distant metastasis rates [26,49].  224 
These data suggest that the outcome of HPV+ HNSCC patients is strongly determined by radiation 225 
biology. Possible mechanisms influencing this response are highlighted in the following paragraphs.  226 
4. Biological basis for the treatment response 227 
As previously mentioned, HPV+ HNSCC patients are associated with better outcome after treatment 228 
with RT [2,12,19,23-25,43,44,50]. The biological basis of this difference is still an intense area of 229 
investigation.  230 
Over the last couple of years several hypotheses have been put forward correlating RT response to 231 
micro–environmental (immune system and hypoxia) and tumor intrinsic factors [12,51]. It has been 232 
hypothesized that the immune system plays a more important role in clearance of HPV+ HNSCC 233 
compared to HPV- HNSCC due to the expression of viral proteins. Recent studies, showing an 234 
increase in immunogenic potential induced by RT, provide a solid base for the hypothesis in which 235 
RT outcome of HPV+ HNSCC is related to the increased immunogenic cell death induced by RT 236 
[12,52,53]. In concordance with this, preclinical data showed better tumor control after ionizing 237 
radiation (IR) in immune-competent HPV+ cell line based mouse models compared to 238 
immune-compromised mice [54].  239 
One of the most studied environmental factors in relation to RT response is hypoxia, which is known 240 
to result in radiation resistance [12,32]. The most interesting study that highlighted the possible 241 
influence of hypoxia in radiation sensitization in HPV+ HNSCC was the retrospective sub-group 242 
analysis by the Danish Head and Neck Cancer (DAHANCA) group. This study showed that the 243 
hypoxic radiation sensitizer nimorazole did not improve the LRC in the HPV+ patient group [55]. 244 
However, currently published data regarding the association between HPV status and tumor 245 
hypoxia is ambiguous. Several studies showed no significant association between HPV and 246 
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surrogate markers for hypoxia such as pO2 measurements, CAIX staining and hypoxic gene 247 
expression profiling [12,56-59]. However, recent publish study by Hanns et al. claimed that HPV 248 
related head and neck cancer showed lower expression of hypoxia related genes and which they 249 
relate to the ability to adapt to hypoxia [60]. However, it is possible to state that to date no clear 250 
experimental evidence is given for the resistance of HPV+ cancers to hypoxic sensitizers and the 251 
possible influence of hypoxia on RT sensitivity.  252 
Several preclinical studies in HPV+ HNSCC indicated the importance of tumor intrinsic factors to 253 
the RT response. These studies can be classified in two categories according to the influenced 254 
pathways namely the influence of HPV on cell cycle and cell death pathways and the influence of 255 
HPV on DNA damage response (DDR) and DNA repair [12,61].  256 
One of the first studies, which not only showed the increased radiation sensitivity of HPV+ HNSCC 257 
cells but also investigated the possible influence of HPV on cell cycle progression and apoptosis, was 258 
performed by Kimple et al. They demonstrated that expression levels of residual wild-type TP53 259 
protein is enhanced by IR and resulted in prolonged G2/M phase arrest and cell death [62]. 260 
Interestingly, another study conducted by Pang et al. demonstrated that indeed introduction of E6 261 
expression in HPV- HNSCC resulted in increased RT response by cell cycle regulation and cell 262 
death, but in a TP53 independent manner [63]. The accumulation of cells in G2/M phase with 263 
accompanied cell death and increased DNA damage was also described by Arenz et al [64].  264 
Gubanova et al. showed that the expression of HPV oncogenes in HPV- cells results in promoter 265 
methylation and decreased expression of serine/threonine-protein kinase-1 (SMG-1), which resulted 266 
in radiation sensitization. Moreover, SMG-1 seems to correlate with HPV status and improved 267 
survival in HNSCC patients [65]. A second paper highlighted the importance of DNA repair in RT 268 
response. This study demonstrated that HPV+ cells have an impaired DNA repair, more specific 269 
defective double strand break (DSB) repair, and a prolonged G2/M phase after IR. No difference in 270 
apoptosis between HPV+ and HPV- cells was noted [66]. Interestingly, Park et al. ascribed the 271 
radiosensitivity of HPV+ cells to E7 oncogene induced delay in sub-lethal DNA damage repair [67]. 272 
In another study Dok et al. showed that HPV+ tumors have not only impaired DNA damage 273 
response, but also showed that this response was related to the expression of p16INK4A. Namely, 274 
they demonstrated that p16INK4A expression resulted in defective homologous recombination 275 
repair (HRR) by impairing the recruitment of RAD51 to the site of DNA damage. This function of 276 
p16INK4A was independent from its cell cycle regulatory function [68].  277 
5. Possibilities to increase the current therapeutic window  278 
The current treatment options are still suboptimal for both groups of HNSCC patients due to high 279 
resistance and recurrence (HPV-) and high toxicity (HPV- and HPV+) issues [2,38,61,69,70]. It should 280 
be kept in mind that the slopes of clinical dose-response curves indicate that enhancement of dose of 281 
RT by just 10% will increase tumor control rates by 5-30% depending on tumor sites and current 282 
control rates [61,71]. Since, it is not possible to increase the total radiation dose to the entire tumor 283 
due to high levels of normal tissue toxicity novel therapeutic approaches are needed. The success of 284 
these novel treatments will be determined by understanding biological processes in HNSCC and 285 
several options are briefly mentioned in the following paragraphs [12,19,32,61]. 286 
De-intensification of current therapy options 287 
Since HPV+ HNSCC patients have better therapy response rates, clinical trials assessing the 288 
possibility to de-intensify the current standard treatment options are ongoing [12,19,32]. These trials 289 
have reduction of acute and late toxicities associated with current aggressive treatment options in 290 
mind and can roughly be divided into two categories: de-intensification of chemotherapy by 291 
replacement by cetuximab, a chimeric monoclonal antibody against EGFR, and de-intensification of 292 
the radiation dose. Current trials de-escalating RT dose in HPV+ HNSCC patients are either in 293 
combination with induction chemotherapy or minimal invasive surgery. In these trials good 294 
responding patients are selected according to the response to the given neo-adjuvant treatment 295 
before a reduction in the radiation dose is made [12,72].  296 
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However, caution must be taken with this kind of trials since the significantly better response seen in 297 
HPV+ HNSCC patients can be a consequence of the received aggressive treatment. On top, 298 
development of de-escalation strategies can be detrimental in approximately 10% of HPV+ HNSCC 299 
patients with high risk of developing distant metastasis [49,73]. 300 
Targeted molecular agents 301 
Although several laboratory studies show that targeting of aberrant oncogenic/mitogenic signal 302 
transduction pathways can result in radiation sensitization of tumors, translation of this 303 
combination treatment strategy to clinical trial settings is rare. Furthermore, it is noteworthy that 304 
multiple recent attempts to use molecular targeted agents for treatment of cancer patients have 305 
failed due to suboptimal dosing and scheduling as well as the lack of biomarkers that predict 306 
response to these targeted therapies [38,61].  307 
Until recently, EGFR amplification or overexpression was seen as one of the most 308 
important aberrations in HNSCC patients leading to the development of EGFR inhibitors 309 
including monoclonal antibodies (mAb) as well as tyrosine kinase inhibitors (TKI) 310 
[19,31,32,50].  311 
Cetuximab was one of the first developed and the only Food and Drug Agency (FDA) and 312 
European Medicines Agency (EMA) approved targeted agent for HNSCC patients in 313 
combination with radiotherapy in locally advanced disease or in combination with 314 
platinum-based chemotherapy in recurrent or metastatic disease [2,50,74]. However, the 315 
survival benefit (10-15%) seen as a single treatment agent is disappointing. It is true that 316 
combination of cetuximab with radiotherapy showed significant improvement in LRC as 317 
well as OS without additional toxicity to patients [12,75]. However, because of the lack of 318 
clinical evidence for the superiority of this treatment over platinum-based standard 319 
therapies it is difficult to make straightforward conclusions regarding the value of this 320 
treatment option. 321 
Additionally, genetic studies show that alterations in the EGFR pathway are rare (21%) and 322 
predominant in the HPV- population (15% HPV- vs 6% HPV+), which suggest that these inhibitors 323 
are less likely to work in HPV+ HNSCC patients [19,31,34,50,76,77].  324 
Interestingly, as mentioned before in the context of de-intensification of current treatment options 325 
for HPV+ HNSCC, three ongoing phase III trials (RTOG 1016, De-ESCALaTE and TROG 12.01) with 326 
similar concepts make use of cetuximab in combination with RT as a treatment arm and cisplatin in 327 
combination with RT as the standard arm [72]. The rationale for these studies is based on subgroup 328 
analysis from the Bonner trial testing the efficiency of cetuximab plus radiotherapy compared to 329 
radiotherapy alone [75,78]. Even though the study did not involve HPV testing, the patients who 330 
benefited most from concurrent cetuximab treatment had characteristics of HPV+ HNSCC patients. 331 
Recently, a secondary analysis of this study was performed in oropharyngeal cancer patients in 332 
whom the p16INK4a as the HPV status was determined retrospectively. The addition of cetuximab 333 
to RT increased the LRC, OS and progression free survival (PFS) in both patients with p16INK4a 334 
positive as p16INK4a negative head and neck cancers [79]. In line with these results the EXTREME 335 
trial showed that addition of cetuximab to the standard chemotherapy resulted in improved OS as 336 
well as PFS, both in p16INK4a/HPV+ and p16INK4a/HPV- HNSCC [45,48]. In contrast, the 337 
SPECTRUM trial, panitumumab (another EGFR monoclonal antibody) in combination with 338 
chemotherapy improved OS only in p16INK4a/HPV- patients [45,47].  339 
Despite these discrepancies, there are still several EGFR inhibitors, mAb as well as TKI, in clinical 340 
trials. To increase the success rate of these kinds of therapies the inhibition should not only be 341 
targeted but also biomarker driven [19,31,37,38,61].  342 
 343 
Aberration and subsequent activation of PI3K pathway is one the most frequent events seen in 344 
HNSCC patients (34% in HPV- and 56% in HPV+) [34]. Activating mutations of the PIK3CA gene 345 
have been reported in 8-21% of head and neck tumors, with an enrichment of mutations in HPV+ 346 
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(37%) patients in comparison with HPV- patient population (18%) [19,31,34]. Furthermore, it has 347 
been reported that some HPV associated HNSCC cases showed only PIK3CA alterations. This 348 
suggests that PIK3CA mutations may have an important role in the development of HPV+ HNSCC 349 
as it has been hypothesized for cervical cancers [50].  350 
Therefore, a tremendous interest has been shown for the inhibition of this pathway by 351 
mTOR/PIK3CA inhibitors. Although, the activity of PI3K inhibitors as single agents in lung 352 
squamous cell cancer patients with PTEN/PIK3CA mutations are disappointing. A preclinical study 353 
performed in HNSCC mouse model showed selective efficiency of PI3K inhibition in PIK3CA 354 
mutated samples [31,80,81]. 355 
Moreover, preclinical data indicate that PI3K pathways inhibitors show a great potential as radiation 356 
sensitizers. Based on these data currently a Phase Ib study, where the combination of pan PI3K 357 
inhibitor with weekly cisplatin and radiotherapy is tested, is ongoing in locally advanced HNSCC 358 
patients (NCT02113878). Additionally, several clinical trials are testing the combination of PI3K 359 
pathway inhibitors with chemotherapy or cetuximab [31,38].  360 
The fibroblast growth factor receptor (FGFR) pathway was another targetable oncogenic pathway 361 
that emerged from latest sequencing data and is currently being tested in several early phase clinical 362 
trials [19,31,34,38]. Preclinical studies in HNSCC cells without prior characterization of genetic 363 
alterations showed anti-tumor effects.  364 
Also, the inhibition of other oncogenic signaling cascades, such as  janus kinase (JAK) and signal 365 
transducer and activator of transcription  (STAT) and RAS pathways, are currently under 366 
investigation in early phase clinical trials [19,31,38].  367 
Moreover, CDK4/6 inhibitors have shown to be effective as single agents in early clinical trials in 368 
breast cancer patients. Since alterations in CDK4/CDK6/CCND1 are common in (HPV-) HNSCC, 369 
inhibition of this pathway looks promising. At present, a clinical trial is ongoing including HNSCC 370 
patients with refractory or relapsed tumors [19,31,38]. Since the above-mentioned alterations are 371 
most common in HPV- HNSCC patients, they will be likely the target audience for these therapies. 372 
In conclusion, targetable oncogenic alterations show great potential for the development of novel 373 
strategies for HNSCC patients (see figure 2 for a short overview). However, the importance and the 374 
current absence of stratification of patients to these strategies and the under-usage of RT 375 
combination strategies should be underlined.  376 
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Figure 2: A short overview of most common altered oncogenic pathways in HNSCC with possible 378 
target sites. 379 
DNA repair as targeting strategy 380 
RT or IR causes ionized molecules within biological tissues. These molecules are highly reactive and 381 
trigger a rapid cascade of damage affecting the molecules in cells. The high copy number of 382 
molecules or proteins will result in rapid turn-over, making the radiation induced damage to these 383 
molecules less significant for cellular survival. However, DNA has only two copies and a 384 
limited-turn over making DNA damage the most important mediator of cellular response to IR. 385 
Therefore the ability to sense DNA damage and control DNA repair is central for RT response 386 
[51,61]. 387 
As previously mentioned, effect of RT is directly linked to induced DNA damage which triggers 388 
DNA damage response (DDR). DDR on one hand initiates cell cycle arrest by checkpoint activation, 389 
giving the cell the opportunity to repair damaged DNA and on the other hand activates the DNA 390 
repair mechanisms. Especially double-strand breaks (DSB) have a high lethality when left 391 
unrepaired [51,61,82-84].  392 
To understand the importance and possibilities of DNA repair, one should know the major DNA 393 
repair mechanisms in mammalian cells. The major repair mechanisms can be divided in 5 pathways. 394 
Most of the direct DSB are repaired by non-homologous end-joining (NHEJ), whereas replication 395 
associated DSB are repaired by HRR. Thus, the choice of repair is cell cycle dependent with NHEJ 396 
preferred in G0/G1 phase of cell cycle and HRR taking place during S/G2/M cell-cycle phases [82-84].  397 
Characteristic for NHEJ is the lack of use of homologous sequences as repair templates, leading to an 398 
error-prone repair. The NHEJ is divided in two pathways being the classical pathway (c-NHEJ) and 399 
alternative pathway (alt-NHEJ) (see figure 3 for a short overview).  400 
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 401 
Figure 3: A short overview of DNA double strand break (DSB) repair mechanisms. 402 
 403 
The classical pathway directly ligates the free ends at DSB and is initiated by KU70/80 DNA 404 
end-binding. This binding protects broken ends and initiates the recruitment of the catalytic subunit 405 
or DNA-dependent protein kinase (DNA-PKcs) and the nucleases. The nucleases are necessary for 406 
free end-processing and will lead to more efficient ligation. Subsequent phosphorylation and 407 
activation of DNA-PKcs will result in the dissociation of the complexes from DNA-ends. This in turn 408 
will enhance the access of the Ligase IV/XRCC4/XLF protein complex which completes the ligation 409 
reaction [82-84]. 410 
 411 
Defects in classic NHEJ proteins channels DSB toward the alternative NHEJ (alt-NHEJ) pathway. 412 
This pathway requires micro-homology and is regulated by PARP1, which will bind to the free 413 
DNA-ends instead of the Ku complexes. PARP1 binding will stimulate single-strand end-resection 414 
by the MRE11/RAD50/NBS1 (MRN) and CtIP protein complexes. Hereafter ligation will take place 415 
as is described for the classical NHEJ pathway. Since this pathway involves limited end-processing 416 
and micro-homology; it will result in even more inaccurate repair [82-84].  417 
In contrast, HRR uses homologous DNA sequences as a template for reparation of DNA damage 418 
(see figure 3 for a short overview). The genetic information is copied typically from sister chromatids 419 
in S/G2 phase and homologous chromosomes and repeated DNA sequences on chromatids can also 420 
be used. Because of the use of homology this mechanism is accepted as a more accurate way of DNA 421 
repair. The HRR process is also classified in an accurate and inaccurate pathway. 422 
 423 
Both of the DNA repair processes start with single-strand DNA end-resection that is divided in 2 424 
phases starting with limited end-resection initiated by MRN/CtIP complexes and is followed by 425 
extensive end-resection by helicases (BLM) and nucleases (EXO1 and DNA2) [82-84].  426 
The accurate or the classical HRR pathway involves the binding of Replication protein A (RPA) to 427 
single-stranded DNA (ssDNA) that will result in stabilization of ssDNA which is necessary for 428 
binding and invasion of the homologous template strand, a process mediated by RAD51 429 
nucleoprotein filaments. The invading strand is extended by newly synthesized DNA, which can 430 
subsequently anneal with the other resected-end. Finally, additional synthesis and ligation will 431 
result in high-fidelity repair. The inaccurate HHR or the single strand annealing (SSA) is 432 
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characterized by the exposure of long complementary ssDNA repeats, which flank the DSB. 433 
Annealing of DNA is mediated by RAD52 leading to the deletion of one of the repeats and the DNA 434 
sequences between the repeats or to translocations when 2 DSB occur in different chromosomes 435 
[82-84].  436 
The 3 other pathways operate on repair of single strand breaks (SSB) after induction with DNA 437 
damaging agents. These are termed base excision repair (BER); nucleotide excision repair (NER) and 438 
mismatch repair (MMR) and they use the complementary strand as a repair template [82-84].  439 
 440 
It is becoming clear that these pathways do not act as separate entities and that there is a functional 441 
overlap between the pathways. This not only shows the complexity of DNA repair processes but 442 
also provides the opportunities to target these pathways to improve the radiotherapeutic index 443 
[61,82,84]. 444 
Targeting DNA repair by modulating radiotherapy response 445 
Since RT results in DNA damage inhibition of DNA repair pathways can be exploited for radiation 446 
sensitization strategies. As mentioned before, deficiencies in DSB repair pathways are thought to be 447 
the most lethal lesions induced by IR. However, it has become apparent that acquired secondary 448 
DBS through deficient SSB repair is also important for the survival of cells after IR [61,82,84].  449 
This knowledge led to the development of a range of novel compounds that influence DNA repair. 450 
For example inhibitors of important molecules in DSB repair, such as DNA-PKcs and PARP 451 
inhibitors have been shown to sensitize cancer cells to RT. Both strategies block DNA repair, thereby 452 
increasing damage in the treated cells and resulting in an increased cell death. Noteworthy is that 453 
such approaches do not necessarily provide selective eradication of cancer cells as they also 454 
influence normal cells [61,82,84].  455 
Although cancer cells need repair mechanisms to survive they are also often defects in one or more 456 
aspects of DNA repair, which lead to an addiction and reliance to the other/back-up DNA repair 457 
pathways. This overreliance or addiction of cancer cells for specific DNA repair pathways can be 458 
therapeutically exploited by inhibiting the back-up DNA repair pathways and is called synthetic 459 
lethality. The best example of a synthetic lethality approach is the use of Poly (ADP ribose) 460 
polymerase (PARP1) in BRCA1/2 mutated breast and ovarian cancers. The inhibition of PARP1 in 461 
these cancers resulted in the accumulation of single strand breaks (SSB) leading to DSB and 462 
eventually cell death upon cellular replication [61,82,84,85]. 463 
In line with this, cancer cells with aberrations in their repair mechanisms are expected to shift their 464 
repair to less common used back-up DNA repair pathways in response to IR, this compared to 465 
normal cells where the common used DNA repair mechanism is still intact. Inhibition of the back-up 466 
DNA repair pathway used by the tumor cells can result in a relative tumor selective radiation 467 
sensitization [61,84]. 468 
Another advantage of combining synthetic lethal drugs with DNA damaging agents, like RT instead 469 
of using as a single therapy modality, is the possibility to avoid resistance. Since synthetic lethal 470 
drugs inhibit DNA repair components, it will also result in an increased mutation rate of the repair 471 
pathways and as a consequence the cancer cell can activate the repressed DNA repair pathways by 472 
additional mutations as it is noted for BRCA2 and PARP inhibition [61,84,86].  473 
6. Biological markers in HNSCC 474 
An important and currently lacking aspect of targeted or personalized medicine is the stratification 475 
of patients who will benefit from novel treatment options or treatment adaptions, as it is currently 476 
tested in the de-intensification trials for HPV+ HNSCC patients. In this regard, the establishment of 477 
molecular markers is of utmost importance.  478 
The marker should be reliable, well-validated and easy to perform and interpret. The establishment 479 
of such robust therapeutic biomarkers has several challenges such as the heterogeneity of the 480 
tumors, role of clinical characteristics and additive influence of conventional risk factors such as 481 
tobacco and alcohol exposure [12,32,50]. 482 
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Currently, HPV positivity in HNSCC cancers is accepted to be a prognostic marker for outcome and 483 
is currently assessed in several institutions. However, assessment of HPV infections has ongoing 484 
challenges with influence of classic risk factor such as tobacco exposure on the favorable outcome of 485 
HPV+ patients and the limitations in the diagnostic testing methods [12,32].  486 
Accurate detection of HPV+ HNSCC patients is still an area of intense discussion. While HPV 487 
specific testing seems logical to use, the implementation in practice is complicated. Currently HPV 488 
testing can be divided in two categories, namely detecting the presence of the virus (direct methods) 489 
and using p16INK4a expression as biomarker for viral infections (indirect method) [12]. Viral DNA 490 
can directly be detected by southern blotting and by the highly sensitive Polymerase Chain Reaction 491 
(PCR). It should be noted that PCR techniques are known to have high false-positive rates due to 492 
their high sensitivity to HPV genome that may be present in tissue biopsies but which is unrelated to 493 
cancer [12,87].  494 
This also highlights a major limitation of HPV-based DNA detection techniques namely these 495 
techniques detect the presence of HPV but not all HPV infections result in cancer formation. In other 496 
words, the clinically relevant HPV detection method is the one that is able to detect the 497 
transcriptionally active form of HPV [12,87].  498 
There are several direct methods that correlate with biologically active HPV infections, including 499 
in-situ hybridization (ISH), RT-PCR for E6 and E7 mRNA and next-generation sequencing 500 
technologies. All of these techniques have the advantage that they have a high specificity and 501 
acceptable sensitivity, while the implementation in practice and the high costs are major 502 
disadvantages [12,87]. 503 
An alternative, which also detects transcriptionally active HPV, is the assessment of p16INK4a 504 
expression by IHC. P16INK4a expression correlates well with direct HPV detection methods as was 505 
shown in a pooled analysis comparing direct HPV detection methods with p16INK4a IHC with only 506 
in about 13% of cases discrepancies [87,88]. One of the major advantages of p16INK4a IHC is that it 507 
is a quick, inexpensive, and a readily available technique [12,87]. On top, several studies using 508 
p16INK4a IHC as a surrogate marker for HPV demonstrate that p16INK4a expression significantly 509 
correlates with outcome, independent of treatment modality.  This is even the case after correction 510 
for other variables by multivariate survival analysis [44,89,90]. Moreover, recently these findings 511 
were verified in a meta-analysis [91]. 512 
However, one of the major disadvantages, that also prevent the general acceptance of p16INK4a IHC 513 
as gold standard, is the low specificity. The low specificity is systematically seen in several studies as 514 
10-20% of p16INK4a+ tumors are HPV-. Although several papers have shown the prognostic 515 
significance of p16INK4a even in the absence of HPV positivity there are contradictory studies 516 
showing significant poor survival rates for HPV-/p16INK4a+ HNSCC patients compared to 517 
HPV+/p16INK4a+ HNSCC patients [87,92-95].  518 
The current debate around the specificity and correlation with outcome is the reason why several 519 
groups are cautious in using p16INK4a IHC as a standalone marker and are suggesting p16INK4a 520 
IHC as an initial screen for direct HPV detection methods. Of note, the cause of p16INK4a 521 
expression in HPV- cases is still unclear but likely to be due to mutations in p16INK4a/RB pathway 522 
[12,15,87,94]. Nevertheless, there is an emerging view that p16INK4a is a suitable single (surrogate) 523 
marker for HNSCC patient stratification but the universal guidelines for interpretation are lacking. 524 
One of the practical problems is the absence of a validated antibody. Second problem is 525 
interpretation of p16INK4a IHC, as currently the cut-off values vary from >10-70% positive staining. 526 
Furthermore, p16INK4a expression shows differences in expression pattern which makes the 527 
interpretation of the function of p16INK4a in these tumors difficult [12,15,87].  528 
7. Conclusions  529 
It is clear that HPV related HNSCC form a distinct entity and that current treatment options are not 530 
answering to the need of these patients. De-intensification of current therapeutic schemes with 531 
molecular targeted agents in combination with standard treatment forms an interesting strategy to 532 
increase the (radio)-therapeutic index. However, these strategies also highlight the importance and 533 
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need for prognostic and predictive biomarkers for stratification of patients. Emerging data generated 534 
by high-throughput technologies will give us valuable information in this regard but it will also 535 
bring novel challenges regarding to interpretation of clinical relevance of these data and feasibility to 536 
clinical translation. This highlights the importance of molecular validation of biological data, but 537 
also indicates the importance of understanding and anticipating at the possible interaction between 538 
different treatment modalities. 539 
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